Investor Presentaiton

ersonal use only 22 22 Driving growth through expanding indications Priority target is Ventricular Tachycardia (VT) driven by growing procedure rates and high value of iCMR for VT 1 Ventricular Tachycardia aorta • Ablation in the left and right ventricles superior vena cava pulmonary artery • Often uses transseptal puncture kit (in Imricor product pipeline) • · • . Requires tracking and mapping system (from MRI manufacturer) Requires defibrillation in MRI (3rd party device in development) Requires 12-lead ECG in MRI (3rd party device in development) All required devices on track for use in VT clinical trial 2 Atrial Fibrillation pulmonary vein right atrium- pulmonary valve tricuspid valve inferior vena cava . Ablation in the left atrium • · • Requires transseptal puncture kit (in Imricor product pipeline) Requires tracking and mapping system (from MRI manufacturer) Benefits from defibrillation and 12-lead ECG in MRI pulmonary vein left atrium mitral valve aortic valve right ventricle -left ventricle Imricor FY20 Investor Presentation, February 2021

View entire presentation